Statin-Associated Myopathy with Normal Creatine Kinase Levels
Top Cited Papers
- 1 October 2002
- journal article
- case report
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 137 (7) , 581-585
- https://doi.org/10.7326/0003-4819-137-7-200210010-00009
Abstract
Muscle symptoms in patients who are treated with statins and have normal creatine kinase levels are not well understood. To report biopsy-confirmed myopathy and normal creatine kinase levels associated with statin use. Case reports from preliminary analysis of an ongoing clinical trial. Clinical research center in a community hospital. Four patients with muscle symptoms that developed during statin therapy and reversed during placebo use. 1) Patients' ability to identify blinded statin therapy and 2) standard measures of functional capacity and muscle strength. All four patients repeatedly distinguished blinded statin therapy from placebo. Strength testing confirmed weakness during statin therapy that reversed during placebo use. Muscle biopsies showed evidence of mitochondrial dysfunction, including abnormally increased lipid stores, fibers that did not stain for cytochrome oxidase activity, and ragged red fibers. These findings reversed in the three patients who had repeated biopsy when they were not receiving statins. Creatine kinase levels were normal in all four patients despite the presence of significant myopathy. Some patients who develop muscle symptoms while receiving statin therapy have demonstrable weakness and histopathologic findings of myopathy despite normal serum creatine kinase levels.Keywords
This publication has 17 references indexed in Scilit:
- Learning from the cerivastatin experienceThe Lancet, 2001
- Concomitant use of cytochrome P450 3A4 inhibitors and simvastatinThe American Journal of Cardiology, 1999
- CorrespondenceAtherosclerosis, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Myopathy Induced by HMG–CoA Reductase Inhibitors in Rabbits: A Pathological, Electrophysiological, and Biochemical StudyToxicology and Applied Pharmacology, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events*Clinical Pharmacology & Therapeutics, 1995
- In Vitro Myotoxicity of the 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors, Pravastatin, Lovastatin, and Simvastatin, Using Neonatal Rat Skeletal MyocytesToxicology and Applied Pharmacology, 1995
- Comparison of Plasma Profiles of Lovastatin (Mevinolin), Simvastatin (Epistatin) and Pravastatin (Eptastatin) in the DogClinical Drug Investigation, 1990
- Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy.Proceedings of the National Academy of Sciences, 1989